WaveMan
WaveMan · Company
BIOA · Bioage Labs, Inc.
> Search tickers & screens ⌘K
LIVE
← All companies

BIOA BioAge Labs (BIOA) Insider Trading, Ownership & Congress Trades

Pharma & Biotech · Pharmaceutical preparations · CIK 0001709941
Quote by TradingView
SEC filings
Insider buyers, 180 days
0
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
90
13F, latest reported quarter
Conversions, 180 days
8
Codes C/M, not in net · $394.6K priced

What the filings say about BIOA

Insiders, 180 days
-$1.6M net sold
1 seller · 0% of sales under a 10b5-1 plan

BioAge Labs insider trades (Form 4)

Form 4 buys and sells (codes P and S). Grants, option exercises and conversions excluded.

Over the last 180 days, BioAge Labs, Inc. insiders sold a net $1.6M of stock across 26 Form 4 purchases and sales, with no insider buying. Source: SEC Form 4 filings, as of 2026-10-28.

Insider
Filed
Shares
Value
Since filing
Barton Shane
Principal Accounting Officer
SELL
2026-07-01 SECtraded 2026-06-30
20,216
$509.2K
-78.2%
Context
  • 2 earlier Form 4 trades (code P or S) here by this insider (1 buy, 1 sale), the last on Jun 29, 2026.
  • No other insider sold within 30 days.
  • 90 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Principal Accounting Officer Barton Shane sold about $509.2K of BIOA on Jun 30, 2026; 90 funds added in the latest 13F quarter.
Barton Shane
Principal Accounting Officer
SELL
2026-07-01 SECtraded 2026-06-29
42,350
$1.1M
-78.2%
Context
  • 1 earlier Form 4 trade (code P or S) here by this insider (1 buy), the last on Sep 27, 2024.
  • No other insider sold within 30 days.
  • 90 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Principal Accounting Officer Barton Shane sold about $1.1M of BIOA on Jun 29, 2026; 90 funds added in the latest 13F quarter.
RUBIN PAUL D
Chief Medical Officer
SELL
2026-04-03 SECtraded 2026-04-01
8,820
$157.1K
-68.8%
Context
  • 5 earlier Form 4 trades (code P or S) here by this insider (5 sales), the last on Mar 2, 2026.
  • No other insider sold within 30 days.
  • 90 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Medical Officer RUBIN PAUL D sold about $157.1K of BIOA on Apr 1, 2026; 90 funds added in the latest 13F quarter.
RUBIN PAUL D
Chief Medical Officer
SELL
2026-03-03 SECtraded 2026-03-02
7,433
$150.9K
-74.0%
Context
  • 4 earlier Form 4 trades (code P or S) here by this insider (4 sales), the last on Feb 2, 2026.
  • No other insider sold within 30 days.
  • 90 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Medical Officer RUBIN PAUL D sold about $150.9K of BIOA on Mar 2, 2026; 90 funds added in the latest 13F quarter.
RUBIN PAUL D
Chief Medical Officer
SELL
2026-02-03 SECtraded 2026-02-02
7,433
$139.4K
-72.9%
Context
  • 3 earlier Form 4 trades (code P or S) here by this insider (3 sales), the last on Jan 2, 2026.
  • 2 other insiders sold within 30 days.
  • 90 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Medical Officer RUBIN PAUL D sold about $139.4K of BIOA on Feb 2, 2026; 2 other insiders sold within 30 days and 90 funds added in the latest 13F quarter.
26 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
See all insider buying · insider selling
Showing the latest few. to see 21 more transactions and use the screener and CSV export. We store only your email; there is no password.
Seven facts, ranked against the sector · Rank is not a forecast
Insiders
net -$1.6M over 180 days
below 67% of Pharma & Biotech
Congress
no House purchase disclosed in the last 12 months
Funds
90 funds bought in last quarter
more than 64% of Pharma & Biotech
Revenue
no revenue reported in any filing
Margin
-896.1% net margin
below 84% of Pharma & Biotech
Buybacks
no share repurchases reported
Short interest
8.4% of the float short (float per yahoo 2026-10-26) · 3.9 days to cover · settled 2026-09-30
more than 61% of Pharma & Biotech
What changed in the last 30 days
Nothing new filed in the last 30 days

Watch BIOA

A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.

The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
-31.2%12M
-39%+46%+131%+216%2025-102025-122026-022026-042026-062026-082026-10 2026-01-13 · Fortney Kristen sold $4.2M2026-06-29 · Barton Shane sold $1.1M2025-12-04 · RUBIN PAUL D sold $702.1K2026-06-30 · Barton Shane sold $509.2K2026-01-13 · GOLDSTEIN DOV A MD sold $239.6K2025-12-09 · RUBIN PAUL D sold $216.0K2026-01-13 · GOLDSTEIN DOV A MD sold $165.4K2026-04-01 · RUBIN PAUL D sold $157.1K2026-03-02 · RUBIN PAUL D sold $150.9K2026-02-02 · RUBIN PAUL D sold $139.4K2026-01-02 · RUBIN PAUL D sold $95.5K2026-01-13 · GOLDSTEIN DOV A MD sold $86.4K2026-01-13 · GOLDSTEIN DOV A MD sold $40.5K2026-06-30 · Barton Shane filed to sell $509.2K2026-06-29 · Barton Shane filed to sell $1.1M
Insider sellForm 144 (planned sale)
Indexed to 100, dividend-adjusted, not a price chart. When a name files heavily, the largest trades are drawn first.

Who owns BIOA: institutional holders (13F)

13F holdings, latest reported quarter
a16z Capital Management, L.L.C.
3,233,170 sh
$79.2M
BlackRock, Inc.
2,849,077 sh
$69.8M
Cormorant Asset Management, LP
2,390,605 sh
$58.6M
Sofinnova Investments, Inc.
2,293,788 sh
$56.2M
Jupiter Topco LLC
2,144,633 sh
$52.6M

Congress trades in BIOA

No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.

Activist and 5% holders (13D/13G)

No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.

BIOA planned insider sales (Form 144)

Notice of intent to sell, filed before any sale
Barton Shane
Filed 2026-06-30
$509.2K
Barton Shane
Filed 2026-06-29
$1.1M

BIOA mutual fund holders (N-PORT)

Funds ranked by the share of their own portfolio in this stock (N-PORT).
State Street(R) SPDR(R) S&P(R) Pharmaceuticals ETF
$6.4M position · as of 2026-06-30
1.5%
PROFUND VP PHARMACEUTICALS
$167.5K position · as of 2026-06-30
1.5%
Ultra-Small Company Fund
$612.8K position · as of 2026-06-30
0.6%
Direxion Daily Pharmaceutical & Medical Bull 3X Shares
$85.1K position · as of 2026-07-31
0.4%
Invesco Dorsey Wright SmallCap Momentum ETF
$1.6M position · as of 2026-05-31
0.4%
NVIT Small Cap Value Fund
$815.6K position · as of 2026-06-30
0.4%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M · % is the share of the fund's own portfolio
Clinical pipeline
5 registered trials, 2 still running (ClinicalTrials.gov). A status change is dated here weeks before the press release.
1
Phase 1
0 active
4
Phase 2
2 active
What changed recently
A Phase 2 Study to Evaluate the Pharmacodynamics, Safety and Tolerability of BGE-102 in
2026-09-11 · Recruiting → Active Not Recruiting
Phase 2
Matched by sponsor name. Trials run under a subsidiary's own name are not included.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
The complete filing record, in one place.
The record shows a net $1.6M sold by insiders over 180 days, 90 funds added last quarter. Each figure is a federal filing, dated the day it went public.
Backtest this pattern Open the screener
Same sector, ranked by filing activity
Sector by SEC SIC code
UTHRCPIXMRNAREGNLLYALNYMDGLCITRDNAVRTXNUVLTWST

BIOA financials

Net margin
-896.1%
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$10.4M
four quarters, 2025-07-01 to 2026-06-30
Net margin, TTM
-912.3%
net income over revenue, 2025-07-01 to 2026-06-30
Free cash flow, TTM
-$88.1M
operating cash flow minus capex, 2025-07-01 to 2026-06-30
Debt to equity
0.00x
long-term 2025-12-31 (6 months older than the period end) plus current 2026-06-30; equity 2026-06-30
Cash flow to debt
n/a
no debt to cover
Return on equity
-28.2%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets
-26.3%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on invested capital
n/a
tax provision or pre-tax income not filed for the four quarters
Return on capital employed
-31.4%
operating income (EBIT proxy) over average of 2025-06-30 and 2026-06-30 minus current liabilities
P/E, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
Enterprise value
$177.1M
market value at close 2026-10-27 on 2026-07-31 shares, plus long-term 2025-12-31 (6 months older than the period end) plus current 2026-06-30, minus cash 2026-06-30
FCF yield
-35.1%
TTM free cash flow over market value at close 2026-10-27
PEG, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
Price as of 2026-10-27. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
2025-122024-122023-12
Revenue$9.0M$0n/a
Operating income-$92.8M-$78.2M-$48.4M
Net income-$80.6M-$71.1M-$63.9M
EPS (diluted)-2.24-6.63-38.17
Operating cash flow-$81.6M-$51.5M-$37.4M
Cash$188.9M$354.3M$21.6M
Long-term debt$0$2.5M$8.2M
SEC XBRL, fiscal years, as known on 2026-10-28

BIOA Stock Sonar score 5/7 axes

Find similar shapesCompare

BIOA ranks highest on financial health (99th percentile) and profitability (66th), and lowest on insider conviction (16th), among Pharma & Biotech peers.

ProfitHealthInsidersInstitutionsRisk
Profitability
66
Inputs
  • Return on equity-28.2% · 68 pct, sector of 545
  • Return on assets-26.3% · 63 pct, sector of 691
  • Return on invested capitaltax provision or pre-tax income not filed for the four quarters
  • Return on capital employed-31.4% · 66 pct, sector of 576
Financial health
100
Inputs
  • Debt to equity0.00x · 100 pct, sector of 352
  • Cash flow to debtno debt to cover
Insider conviction
16
Inputs
  • Net Form 4 buying (codes P and S), 180d-$1.6M · 31 pct, sector of 428
  • Insider buyers, 180d0 · 0 pct, sector of 437
Institutional and government
64
Inputs
  • Funds adding, latest quarter90 · 64 pct, sector of 698
  • Congress net buyers, 365dno Congress trades in 365 days
  • Federal contracts, 180dno federal contracts in 180 days
  • Lobbying spend, 4 quartersno lobbying filings in the last four quarters
Risk and compliance
65
Inputs
  • Short interest, % of float+8.4% · 45 pct, sector of 813
  • Recalls per $1B revenue, 3yrevenue under $50M or not filed, so a count cannot be scaled to size
  • EPA cases per $1B revenue, 5yrevenue under $50M or not filed, so a count cannot be scaled to size
  • New text in Risk Factors, latest 10-K+4.6% · 85 pct, sector of 511
2 not measured: Growth, US patents
  • Growth needs 1 of 2 inputs, 0 present: no backlog line filed, or no year-earlier backlog; no revenue for this year and the year before
  • US patents needs 1 of 2 inputs, 0 present: patent data not loaded yet

5 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored

BIOA filings, in plain words

Are BioAge Labs insiders buying or selling BIOA?

In the 180 days to 2026-10-28, BioAge Labs insiders were net sellers, a net $1.6M across purchases and sales reported on Form 4, by 1 seller.

Read the full summary

In the 180 days to 2026-10-28, BioAge Labs insiders were net sellers of BIOA, a net $1.6M across purchases and sales reported on Form 4 by 1 seller. Each figure is counted from SEC and House filings as of 2026-10-28, dated the day the filing was made public.

Explore insider trading and ownership data

Every company we track, ranked by each kind of filing
Insider buyingInsider sellingCongress stock tradesActivist 13D stakesForm 144 planned salesCEO pay vs performanceAll companies